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atecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease associated with cardiac arrest in the pediatric population. The disease was first described as a novel clinical entity by Coumel et al 1 in 1978 and then in a follow-up study in 1995. 2 With the advancements of molecular genetics the discovery of the genetic substrate of the disease 3, 4 showed that CPVT results from inherited abnormalities of intracellular Ca 2ϩ regulation caused by dominant mutations in the RYR2 gene, encoding the cardiac Ca 2ϩ release channel (ryanodine receptor isoform 2 [RyR2]) 3 and by recessive mutations in the CASQ2 gene, encoding cardiac calsequestrin isoform 2. 5 The discovery of the molecular substrate of CPVT has fuelled basic science studies to characterize RYR2 and CASQ2 mutations in vitro and in vivo, leading to important advancements in the understanding of intracellular Ca 2ϩ regulation and its relevance to arrhythmogenesis.
In this article, we provide an overview of the developments that have occurred in the 10 years following the discovery of the first RYR2 mutations and the involvement of mutant RyR2 in CPVT patients. We start with the physiology of Ca 2ϩ storage and release in the sarcoplasmic reticulum (SR) and its relevance to rhythm maintenance. We then discuss how mutations in RyR2 disrupt the Ca 2ϩ handling system, leading to cardiac arrhythmias. Finally, we address how the understanding of the pathophysiology of the disease is leading to novel therapeutic strategies.
Fundamental Mechanisms of Intracellular Ca 2؉ Handling
Understanding of the physiology of Ca 2ϩ handling in cardiac cells is critical for understanding how CPVT mutations alter intracellular Ca 2ϩ regulation in the heart. Excitation-contraction (EC) coupling in cardiac muscle is mediated by a mechanism known as Ca 2ϩ -induced Ca 2ϩ release (CICR). 6 During an action potential, the voltage-dependent L-type Ca 2ϩ channel in the transverse T-tubular membrane is activated, resulting in a small influx of external Ca 2ϩ into the cytosol. This Ca 2ϩ binds to the cytosolic Ca 2ϩ sensor in RyR2 located in the sarcoplasmic reticulum (SR) and opens the channel, leading to a large release of Ca 2ϩ from the SR, the major intracellular Ca 2ϩ store containing 1 to 1.5 mmol/L free Ca 2ϩ . 7 The Ca 2ϩ released then binds to troponin C, causing a cascade of conformational changes in the myofilaments and ultimately muscle contraction. During the relaxation phase, SR Ca 2ϩ release is terminated, and the released Ca 2ϩ is recycled back to the SR by the SR Ca 2ϩ -ATPase (SERCA) or extruded from the cell by the Na ϩ /Ca 2ϩ exchanger (NCX), effectively lowering the cytosolic Ca 2ϩ concentration and allowing the dissociation of Ca 2ϩ from the myofilaments and muscle relaxation ( Figure 1 ). 8 It has long been known that SR Ca 2ϩ release can also occur in the absence of cellular depolarization through a mechanism referred to as spontaneous Ca 2ϩ release 9 that is facilitated by the presence of SR Ca 2ϩ overload. 10 -12 Spontaneous SR Ca 2ϩ release can also occur as a result of spontaneous membrane depolarization. [13] [14] [15] To distinguish spontaneous Ca 2ϩ release in the form of Ca 2ϩ waves from depolarization-initiated Ca 2ϩ release and considering its dependence on the size of the SR Ca 2ϩ store, we have proposed that it be designated as Store Overload Induced Ca 2ϩ Release (SOICR). 16 ,17 A number of conditions, including ␤-adrenergic stimulation, digitalis toxicity, elevated extracellular Ca 2ϩ , and fast pacing can lead to SR Ca 2ϩ overload and subsequently SOICR in cardiac cells. 10, 18 For instance, the release of catecholamines leads to the activation of ␤-adrenergic receptors and adenylate cyclase and to an increase of cAMP. The cAMP-dependent protein kinase (PK)A is then activated, leading to the phosphorylation of a number of protein targets, including the L-type Ca 2ϩ channel and phospholamban, an inhibitor of SERCA. Phosphorylation of the L-type Ca 2ϩ channel by PKA increases Ca 2ϩ influx, whereas phosphorylation of phospholamban by PKA relieves its inhibition on SERCA and consequently increases SR Ca 2ϩ uptake. Excessive ␤-adrenergic stimulation would, therefore, lead to augmented Ca 2ϩ influx and SR Ca 2ϩ uptake, resulting in SR Ca 2ϩ overload and subsequently SOICR. In the case of digitalis toxicity, cardioglycosides such as ouabain or digoxin, inhibit the activity of Na ϩ /K ϩ ATPase, resulting in the accumulation of intracellular Na ϩ , which, in turn, inhibits the activity of the NCX. The decrease in NCX activity reduces Ca 2ϩ extrusion from the cell, leading to more Ca 2ϩ being recycled back to the SR, SR Ca 2ϩ overload and SOICR. Similarly, elevated external Ca 2ϩ or fast pacing will increase Ca 2ϩ influx and SR Ca 2ϩ loading and thus the propensity for SOICR. 8 Overall, there are at least 3 major components of the progression to SR Ca 2ϩ overload: (1) increased Ca 2ϩ influx; (2) increased SR Ca 2ϩ uptake; and (3) reduced Ca 2ϩ extrusion ( Figure 1 ).
Electrophysiological Consequences of SOICR:
Delayed Afterdepolarizations, Early Afterdepolarizations, and Triggered Arrhythmias
It has long been recognized that SOICR can alter membrane potential. The large increase in cytosolic Ca 2ϩ as a result of SOICR in the form of Ca 2ϩ waves can activate NCX. Because NCX is electrogenic, activation of NCX will generate a transient inward current. This inward current can depolarize the surface membrane after the action potential is ended, and thus produce delayed afterdepolarizations (DADs). 10 -12 If the amplitude of DADs reaches the threshold for Na ϩ channel activation, DADs can trigger an action potential, which can lead to triggered arrhythmias. 19 -21 Recently, the mechanisms initiating early afterdepolarizations (EADs) have been reassessed. 22 It was suggested that NCX may also be implicated in the generation of EADs. 23 alternans and sudden changes in action potential duration. 24 Interestingly, both the magnitude and the rate of spontaneous SR Ca 2ϩ release events are critical for the determination of whether triggered activity could occur. 25 It has been estimated that a total SR Ca 2ϩ release of 50 to 60 mol/L cytosol, or 50% to 70% of the SR Ca 2ϩ load, is required to produce DADs with an amplitude that is sufficient to trigger an action potential. 21 In addition to Ca 2ϩ waves, spontaneous SR Ca 2ϩ release can occur in the form of brief, localized Ca 2ϩ transients (Ca 2ϩ sparks) 26 or invisible Ca 2ϩ leak through "rogue" RyRs. 27 These small visible or invisible SR Ca 2ϩ leaks as a result of "leaky" RyR2 channels by themselves are unlikely to generate DADs with amplitudes that are high enough to produce an action potential or triggered activity. It is the Ca 2ϩ overload-induced spontaneous SR Ca 2ϩ release in the form of Ca 2ϩ waves (SOICR) that is capable of producing DAD-mediated triggered arrhythmias. 30 It has been proposed that luminal Ca 2ϩ activates RyR2 by passing through the open channel and acting on the cytosolic Ca 2ϩ activation site of the channel. This is known as the "feed-through" hypothesis. 31, 32 However, the finding that single RyR2 channels are still activated by luminal Ca 2ϩ under conditions where luminal-to-cytosolic Ca 2ϩ flux is absent does not support the feed-through hypothesis. 33, 34 As a consequence it was suggested that the luminal Ca 2ϩ is sensed by a luminal Ca 2ϩ activation site distinct from the cytosolic Ca 2ϩ activation site. 33 Recently, it has been proposed that luminal-to-cytosolic Ca 2ϩ flux may be required for a full activation of the RyR2 by luminal Ca 2ϩ . 35 36 Although modulation of RyR2, to some extent, may not have a sustained impact on CICR, it can significantly influence the properties of SOICR. For example, increasing RyR2 activity with low concentrations of caffeine lowers the critical SR Ca 2ϩ concentration at which SOICR occurs and increases its frequency. Conversely, inhibiting RyR2 activity by tetracaine increases the threshold for SOICR and lowers its frequency. 37 As a consequence, even small alterations of RyR2 will have a significant impact on SOICR and thus on the occurrence of DADs and triggered arrhythmias ( Figure 1 ).
Mechanisms of

Role of Calsequestrin in SOICR
Gyorke and colleagues 38, 39 have provided data supporting the view that CASQ2 is the luminal Ca 2ϩ sensor responsible for regulation of RyR2 by luminal Ca 2ϩ , and for the initiation and termination of SOICR. The authors proposed that CASQ2 monomers inhibit RyR2 at low SR Ca 2ϩ concentrations by binding to the complex formed by triadin, junctin, and RyR2. 39 At high SR Ca 2ϩ concentrations, however, CASQ2 monomers assemble into polymers and dissociate from the RyR2 channel complex, thus relieving the inhibition of RyR2, leading to channel activation and spontaneous Ca 2ϩ release. 38 Knollmann et al 40 
Linking Intracellular Ca 2؉ Handling With CPVT
The diagnosis of CPVT is most commonly established in apparently healthy pediatric patients suddenly and unexpectedly manifesting stress-or emotion-induced syncopal episodes. Occasionally, sudden cardiac death is the first clinical event in an otherwise healthy young individual. 44 -46 Unless diagnosed and treated the disease is lethal: in our series of patients, up to 30% of misdiagnosed and affected individuals died suddenly before the fourth decade of life.
The diagnosis of CPVT is challenging considering that cardiological evaluation is often completely normal and patients show unremarkable echocardiogram and ECG. In the absence of a family history indicative of a genetic arrhythmogenic condition, CPVT can be suspected only during exercise stress testing when patients develop exercise-related ventricular tachycardia. During exercise stress test, CPVT patients show isolated premature beats at the beginning of exercise with a progressive worsening of the complexity of ventricular arrhythmias in response to an increased workload. Typically, when the heart rate reaches 90 to 110 bpm, runs of nonsustained or sustained VT appear and they may degenerate into sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) unless exercise is promptly terminated. The morphology of VT is often the hallmark of the disease: the so-called bidirectional VT, 1, 3 which is characterized by a 180°beat-to-beat rotation of the axis of the QRS complexes on the frontal plane (Figure 2) . Interestingly, bidirectional VT is also the typical morphology of ventricular tachycardia in the setting of digitalis intoxication thus suggesting that the 2 arrhythmogenic conditions may share similar electrophysiological bases.
Bidirectional VT is considered the diagnostic marker of CPVT, however, not all patients with the disease manifest this form of arrhythmias. Based on our patient population, we were able to identify different phenotypic manifestations of CPVT among patients with RyR2 mutations: (1) patients presenting reproducible bidirectional VT and polymorphic VT at exercise stress testing; (2) patients presenting only with polymorphic VT; and (3) survivors of cardiac arrest and lacking induction of arrhythmias during exercise stress test. 3 The latter group is intriguing and it is arguable whether they should be considered part of the CPVT phenotype. A subset of these patients, referred for genetic testing with the diagnosis of idiopathic VF, carry RyR2 mutations. It will be of interest to determine whether the impact of these idiopathic VF RyR2 mutations differ from that of the typical CPVT RyR2 mutations.
Molecular screening of the RYR2 and CASQ2 genes importantly contributes to diagnosis in patients with less typical phenotypic manifestations. Functional characterization in vitro as well as knock-in mouse models carrying clinical mutations also provide important information that helps us to understand how abnormalities in RyR2 and CASQ2 disrupt the physiology of intracellular Ca 2ϩ regulation, leading to arrhythmic storms.
RyR2 Mutations Linked to CPVT
The RyR2 channel is a homotetramer with each subunit containing a large cytosolic domain formed by the first Ϸ4300 N-terminal residues and a smaller transmembrane (TM) domain formed by the last Ϸ500 C-terminal residues. The TM domain of RyR2 encompasses the channel pore, whereas the cytosolic domain contains binding sites for a number of channel regulators. In such a large and complex protein, it is challenging to investigate the topology of mutations in an attempt to derive structure-function information.
Mutations in genes encoding the voltage dependent ion channels that cause several clinical diseases, are often distributed across the entire coding region of the genes of interest. RyR2 mutations appear to be preferentially located in four regions (Figure 3 ). The term "domains" indicates those regions, according to this classification, domain I includes amino acids 77 to 466, domain II amino acids 2246 to 2534, domain III amino acids 3778 to 4201 and domain IV amino acids 4497 to 4959 (Figure 4 ). These regions are highly conserved in RyR across species and are superimposable (except for region III) to the localization of RyR1 mutations associated with central core disease and malignant hyperthermia. 47 Mutations in RyR2 are not uniformly distributed across the four domains: mutations in domains III and IV collectively account for 46% of all mutations reported, followed by mutations located in domain II (21%) and by mutations in the N terminus (18%). It has been suggested that only a small number of mutations are positioned in less conserved regions outside the above mentioned domains: Medeiros Domingo et al 48 reported that only 10% of mutations are outside domains I-IV. At variance with this estimation, analysis of our CPVT cohort by direct ORF sequencing indicates that 24% of RyR2 mutations identified in CPVT patients are located outside the four canonical domains.
Most mutations identified in RyR2 are single nucleotide replacements (also called "point mutations") leading to an amino acid substitution: this is at variance with the case for other channelopathies where mutations such as truncations, deletions and insertions are more common. Premature stop codons, frame shifts, and out-of-frame insertions or deletions have not been identified in CPVT patients screened for mutation on the RYR2 gene. The lack of identification of loss of function mutations in RyR2 may be the consequence of the fact that the screening of RyR2 is usually targeted to patients with the CPVT phenotype and structurally intact heart. Therefore, it is possible that loss of function mutations result in different diseases possibly including structural abnormalities of the heart consistent with a cardiomyopathic phenotype. Some authors 49 -52 have suggested that RYR2 mutations may cause arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). 
Small in-frame duplications or in-frame insertions 48, 53 are present in patients with the CPVT phenotype, suggesting that their functional consequences are similar to that of point mutations, rendering the channel more prone to spontaneous SR Ca 2ϩ release during adrenergic stimulation. We have identified 82 RYR2 mutations in our CPVT probands: 79 were point mutations and 3 (3.6%) were small deletions/insertions (one in frame insertion and 2 in frame deletions). Carriers of insertion/deletions had clinical manifestations consistent with CPVT and no structural abnormalities. Bhuiyan et al 54 using multiplex ligation-dependent probe amplification (MLPA) analysis, identified a large deletion encompassing part of intron 2, exon 3, and part of intron 3 associated with a complex clinical phenotype that included progressive AV block and SAN dysfunction, AF, atrial standstill, and depressed LV function to dilated cardiomyopathy (DCM). However, other reports of large deletions in the same region failed to confirm the association with DCM: large exon 3 deletions were reported by Marjamaa et al 55 in 2 apparently unrelated patients. One of these patients showed no major structural abnormalities, whereas the other patient showed increased trabeculation of the left ventricle, suggestive of noncompaction cardiomyopathy. Medeiros-Domingo et al 48 reported a large 3.6 kb exon 3 deletion, but the phenotype of the patient was not reported. Large deletions encompassing exon 3 seem to be relatively frequent, possibly because the region presents Alu repeats that may predispose genomic rearrangements. 56 Whether these cause distinguishing phenotypes in addition to CPVT is still undefined.
Functional Consequences of RyR2 Mutations
Delayed afterdepolarization and triggered activity has been shown in knock-in models of CPVT ( Figure 5 ). 57 A key and fundamental question is what aspects of RyR2 function are impaired by these disease-causing RyR2 mutations. Considering the important role of luminal Ca 2ϩ in triggering SOICR and DADs, Jiang and colleagues 16, 17 directly determined the impact of a number of CPVT RyR2 mutations on the sensitivity of single RyR2 channels to luminal Ca 2ϩ activation in the near absence of cytosolic Ca 2ϩ using single channel recordings in planar lipid bilayers. In these studies, a spectrum of RyR2 mutations were used, extending from the N-to the C-terminus, with small phenotypic differences among carriers: L433P and R176Q/T2504M located in the N-terminal region of the channel; mutations S2246L and R2474S located in the central region; and Q4201R, N4104K, R4496C, I4867M, N4895D, and V4653F 58 located in the C-terminal region. All of these mutations showed a consistent behavior characterized by an enhanced response of the channel to luminal Ca 2ϩ activation. 59 These observations indicate that CPVT RyR2 mutations preferentially sensitize the channel to luminal Ca 2ϩ activation, whereas only a few CPVT RyR2 mutations sensitize the channel to both cytosolic and luminal Ca 2ϩ activation.
In agreement with the role of luminal Ca 2ϩ activation of RyR2 in SOICR, CPVT RyR2 mutations that increase the response of the channel to luminal Ca 2ϩ also enhance the propensity for SOICR in HEK293 cells by reducing the threshold luminal Ca 2ϩ level at which SOICR is triggered. Enhanced SOICR has also been observed in cardiomyocytes isolated from various knock-in mice harboring CPVT RyR2 mutations, R176Q, 60 R4496C, 59 ,61 or R2474S. 62 The same manifestation of CPVT RyR2 mutations in both cardiomyo- cytes and in HEK293 cells, which lack a number of cardiac specific proteins, including CASQ2, suggests that SOICR is not unique to cardiac cells, and is primarily determined by the intrinsic properties of the RyR2 channel. Together, these observations support the view that the luminal Ca 2ϩ sensor of RyR2 is located within its primary sequence and is responsible for the initiation and termination of SOICR.
Although CPVT RyR2 mutations alter the sensitivity of the channel to Ca 2ϩ activation, they apparently have little or no impact on excitation-contraction (EC) coupling, as patients with CPVT RyR2 mutations do not show arrhythmias in unstimulated conditions. 63 64 However, under conditions of SR Ca 2ϩ overload, SR auto-regulation becomes ineffective, resulting in SOICR and, consequently, in DADs and triggered arrhythmias ( Figure 6 ).
How RyR2 Mutations Alter the Sensitivity of the Channel to Luminal or Cytosolic Ca 2؉ Activation?
In the previous section, we have presented robust evidence supporting the view that CPVT RyR2 mutations alter the sensitivity of the channel to luminal and/or cytosolic Ca 2ϩ activation, leading to enhanced spontaneous Ca 2ϩ release during SR Ca 2ϩ overload (SOICR). What remains unclear today is how CPVT RyR2 mutations exert these effects. Two mechanisms have been proposed and will be presented below: Domain unzipping and FKBP12.6 unbinding.
Domain Unzipping
It has been proposed that the N-terminal domain in RyR2 interacts with the central domain, and that CPVT RyR2 mutations in the N-terminal and central domains weaken this interaction (domain unzipping). 65, 66 These domain interactions are believed to be involved in the stabilization of the closed state of the channel. Hence, domain unzipping as a result of mutations would destabilize the closed state of the channel, rendering the channel more sensitive to stimuli, such as luminal or cytosolic Ca 2ϩ . Evidence for unzipping of the interaction between the N-terminal and central domains raises the question of whether "domain unzipping" is present in other regions of RyR2 in which CPVT mutations are located. In support of 
FKBP12.6 Unbinding
Another mechanism by which mutations may alter the sensitivity of the channel to Ca 2ϩ activation is the disruption of critical protein-protein interactions. In this regard, it has been proposed that RyR2 mutations may specifically impair the interaction between RyR2 and the 12.6 kDa FK506 binding protein (FKBP12.6). 70 FKBP12.6 is thought to play an important role in stabilizing the RyR2 channel and dissociation of FKBP12.6 from RyR2 as a result of phosphorylation of RyR2 by PKA during ␤-adrenergic stimulation has been shown to increase the sensitivity of the channel to cytosolic Ca 2ϩ activation. 71 In the hypothesis proposed by Wehrens et al, 70 RyR2 mutations may impair FKBP12.6 binding to RyR2 making the channel leaky. A number of studies have been carried out to determine the impact of CPVT RyR2 mutations on RyR2-FKBP12.6 interaction. Wehrens et al 70 showed that CPVT RyR2 mutations, S2246L and P2328S located in the central region, and Q4201R, R4496C, and V4653F located in the C-terminal region, reduced the affinity of FKBP12.6 binding to RyR2. Based on these observations they proposed that reduced FKBP12.6 binding affinity is a common defect of CPVT RyR2 mutations. Subsequently, Wehrens et al 70 and Lehnart et al 72 showed that the R2474S mutation also decreases the affinity of FKBP12.6 binding.
These findings concerning causative alterations in the binding of FKBP12.6 to RyR2 have not been confirmed in more recent studies. For example, Tiso et al 73 showed that the same R2474S mutation was found to increase the affinity of FKBP12.6 binding. Moreover, Liu et al, 57 studying the R4496C knock-in mouse model, showed that a compound that promotes the binding of FKBP12.6 to RyR2, K201, did not alter arrhythmogenesis in this mouse model. These findings suggest that either FKBP12.6 binding is not critical for arrhythmogenesis in CPVT or that it is critical only for selected mutations. Studies by George et al 16, 74 and Jiang and colleagues 16, 74 then demonstrated that CPVT RyR2 mutations had no effect on FKBP12.6 binding. Recent data from Bers and coworkers demonstrated that PKA is not involved in the dissociation of FKBP12.6 from RyR2, thus questioning any link between RyR2 phosphorylation and FKBP12.6 dissociation. 75 Therefore, whether CPVT RyR2 mutations alter the affinity of FKBP12.6 binding, 16 and the question of whether the dissociation of FKBP12.6 affects cytosolic Ca 2ϩ activation of RyR2 or increases the propensity for ventricular arrhythmias 76 are still highly controversial. Although it may be possible that selected mutations alter FKBP12.6 binding to RyR2, an increasing body of evidence clearly demonstrates that alterations in FKBP12.6-RyR2 interaction are unlikely to be the common cause of CPVT associated with RyR2 mutations.
Functional and Structural Consequences of CASQ2 Mutations
Mutations in the gene encoding the cardiac calsequestrin isoform 2 (CASQ2), mapping to chromosome 1p13.3-p11, causes an autosomal recessive form of CPVT (CPVT2). The first homozygous CASQ2 mutation (D307H) was identified in a large consanguineous Bedouin family and reported by Lahat et al 5 in 2001. As expected for a recessive disease, CPVT2 is much less common than the autosomal dominant form of the disease. As a consequence, eight years after the original description of the first CASQ2 mutations, only a few additional variants have been identified. As of today 12 CPVT-associated mutations and 3 non synonymous polymorphisms (cSNP) are known (http://www.fsm.it/cardmoc/). Among the 12 CPVT CASQ2 mutations, 4 are nonsense mutations that will lead to the expression of a truncated protein. 77, 78 Among the remaining 8 missense mutations, R33Q and D307H have been shown to reduce the level of CASQ2 protein to 5% and 45%, respectively. 79, 80 Hence, both the nonsense and some missense mutations lead to reduced CASQ2 protein levels and consequently reduced SR Ca 2ϩ buffering capacity. The R33Q, K206N, L167H, and D307H CASQ2 missense mutations have also been shown to alter the Ca 2ϩ binding capacity and/or the Ca 2ϩ -dependent polymerization of CASQ2. 79, [81] [82] [83] [84] Because the CASQ2 polymer is responsible for high capacity Ca 2ϩ binding, such alterations will also lead to a reduction in SR Ca 2ϩ buffering capacity. The molecular defects of other missense mutations (Y55C, P308L, E177Q, and F189L) have not been characterized. [85] [86] [87] The Y55C and P308L are compound heterozygous CASQ2 mutations associated with CPVT. 85 Nevertheless, these observations clearly demonstrate that reduced SR Ca 2ϩ buffering capacity is a common consequence of CPVT CASQ2 mutations. Reduced SR Ca 2ϩ buffering will result in a fast recovery of SR free Ca 2ϩ after each Ca 2ϩ release and a potentially higher level of SR free Ca 2ϩ during a sudden increase in SR Ca 2ϩ loading, both of which will increase the propensity for SOICR and thus DADs and triggered activity ( Figure 6 ). Some CASQ2 mutations may alter the interactions between CASQ2 and the RyR2 channel complex, thus affecting the response of RyR2 to elevating luminal Ca 2ϩ . For example, unlike the CASQ2 wt, the R33Q CASQ2 mutant has been shown to be unable to effectively inhibit the RyR2 channel at low SR Ca 2ϩ concentrations. 88, 89 Cardiomyocytes overexpressing the R33Q mutant showed a reduced threshold SR Ca 2ϩ level at which spontaneous Ca 2ϩ release occurs. These observations have led to the proposal that the R33Q mutation may alter the interaction of CASQ2 with the RyR2 channel complex and affect the response of the channel to luminal Ca 2ϩ . 89 However, it is important to point out that CASQ2 null cardiomyocytes exhibit no abnormal SR Ca 2ϩ release at low SR Ca 2ϩ concentrations, and that CASQ2 null mice show no ventricular arrhythmias at rest. 40 Therefore, the significance of CASQ2's inhibitory effect on RyR2 at low SR Ca 2ϩ concentrations is unclear.
The level of CASQ2 has also been suggested to be important in modulating the activity of RyR2. Chopra et al 90 showed that heterozygous CASQ2-null cardiac cells displayed more SR Ca 2ϩ leak than the wild-type control cells at the same free SR Ca 2ϩ concentration. This observation led to the conclusion that a modest reduction in CASQ2 protein level (Ϸ25%) can reduce the threshold for spontaneous SR Ca 2ϩ leak. However, Kubalova et al 91 have demonstrated that increasing (Ϸ3.5 fold) or decreasing (to 30% of control) the level of CASQ2 protein has no effect on the threshold SR Ca 2ϩ level at which spontaneous Ca 2ϩ waves (SOICR) occurs. Changing the level of CASQ2 protein, however, markedly alter the dynamics of SR Ca 2ϩ recovery after SR Ca 2ϩ release. These observations indicate that CASQ2 via its Ca 2ϩ buffering function mainly affects the dynamics of SR Ca 2ϩ recovery or the frequency of SOICR, but not the threshold for SOICR. In this regard, it will be important to determine whether a reduction (25%) of CASQ2 in heterozygous CASQ2-null cardiac cells alters the dynamics and amplitude of free SR Ca 2ϩ concentrations during spontaneous Ca 2ϩ waves. The clinical phenotype of patients affected by the recessive variant of CPVT is virtually identical to the autosomal dominant form except that carriers of homozygous CASQ2 mutation have more severe manifestations than carriers of heterozygous RyR2 mutations. In analogy with humans, mice with homozygous CPVT CASQ2 mutations display phenotypes virtually identical to, but more severe than, those observed in mice with heterozygous CPVT RyR2 mutations, 40,78 -80,92 suggesting that CASQ2-linked CPVT and RyR2-associated CPVT share a common causal mechanism ( Figure 6) 
Therapeutic Approaches to CPVT
The understanding of the basic mechanisms of arrhythmogenesis in CPVT should guide the identification of novel therapeutic strategies. It seems that promising approaches for suppressing CPVT are (1) the prevention of SR Ca2ϩ overload and (2) the resolution of the defect in SOICR by RyR2 modulation.
Agents like ␤-blockers and Ca2ϩ channel inhibitors have been used in experimental as well as clinical settings, primarily act by reducing calcium overload via the reduction of heart rate and L-type Ca2ϩ channel current, and through the inhibition of phosphorylation of phospholamban and thus the activation of SERCA.
Inhibition of RyR2 may also be an important determinant of the effectiveness of antiarrhythmic drugs in CPVT. As suggested by recent data discussed below, flecainide may cause an open state block of the RyR2 channel, which may prevent the arrhythmogenic Ca2ϩ waves without affecting SR leak-load balance.
As of today the clinical management of CPVT aims at attenuating the arrhythmogenic effect of adrenergic stimulation through the use of ␤-blockers.
However, already in 2002, we reported 3 that ␤-blockers can only confer partial protection from life-threatening arrhythmias among patients compliant to therapy with the maximal tolerated dose of ␤-blockers. When patients present recurrence of arrhythmic events on ␤-blockers, they are often implanted with an implantable cardioverter defibrillator. However, given the young age of patients, the use of the defibrillator is often challenging and associated with complications such as lead-fracture and infection of the pocket that contains the generator.
Clearly there are now expectations that recent basic science advancements in the understanding of the disease may guide the development of novel therapies. Prompted by the evidence that CPVT is caused by abnormalities in Ca 2ϩ handling, some authors decided to test the efficacy of verapamil in mice and humans. Sumitomo et al 94 observed that in their cohort of CPVT patients that Ca 2ϩ antagonists partially protected patients from arrhythmic events. A few years later Swan et al 95 reported suppression of arrhythmias during exercise stress test with verapamil, yet they did not report the survival benefit of the drug. In our experience, verapamil and diltiazem show a partial improvement of frequency of arrhythmic events but their effect is not sufficient to avoid the need for an implantable defibrillator. The molecular mechanism by which verapamil effectively suppresses CPVT is unclear: in vitro studies have suggested that verapamil may bind to RyR2 and inhibit its channel activity. 96 However, whether this mechanism is present at clinically relevant concentrations of the drug, has not been established.
Recently, in vitro data showed that, in analogy with Ca 2ϩ channel blockers, flecainide, a Na ϩ channel blocker, inhibits single RyR2 channel activity and suppresses spontaneous SR Ca 2ϩ release in cardiac cells. 97, 98 Interestingly, the drug was also found to suppress ventricular arrhythmias in the CASQ2-knock-out mouse model of CPVT. Whether the antiarrhythmic activity of flecainide is dependent on its RyR2 blockade 95 or on the sodium channel blocking activity that reduces the probability for DADs to reach the threshold for action potential generation, 99 is still uncertain. The antiarrhythmic effect of flecainide, however, seems to be confirmed in patients, thus providing an important therapeutic breakthrough.
Animal studies have proposed additional therapeutic strategies that have not been tested in humans. K201(JTV519), a 1,4-benzothiazepine derivative that shares a high degree of structural similarity with the L-type channel blocker diltiazem, was originally discovered on the basis of its ability to protect cardiomyocytes from cell injury and death resulting from Ca 2ϩ overload induced by epinephrine, caffeine, and high external Ca 2ϩ . 100 K201 is thought to inhibit RyR2 and prevent SR Ca 2ϩ leak by stabilizing FKBP12.6 binding to RyR2. However, recent studies revealed that K201 binds to the central region of RyR2 (2114 to 2149 aa) 101 and suppresses SR Ca 2ϩ leak and spontaneous Ca 2ϩ waves irrespective of FKBP12.6 association. 101, 102 Despite its inhibitory action on RyR2 and spontaneous Ca 2ϩ release, K201 was found to be unable to prevent ventricular arrhythmias in the R4496C ϩ/Ϫ knock-in mouse model of CPVT, 57 although it is able to prevent ventricular arrhythmias in FKBP12.6 ϩ/Ϫ mice. 103, 104 Because human studies with K201 or its derivative have not yet been completed, the clinical role of these agents remains to be defined.
An increasing body of evidence indicates that the Ca 2ϩ and calmodulin-dependent protein kinase (CaMK)II plays an important role in the generation of spontaneous SR Ca 2ϩ waves on ␤-adrenergic stimulation. 105 Suppression of the CaMKII pathway may, therefore, represent another effective therapeutic approach for the suppression of Ca 2ϩ -mediated arrhythmias. In support of this idea, preliminary evidence shows that KN93, an inhibitor of CaMKII, is able to prevent ventricular arrhythmias in the R4496C ϩ/Ϫ mouse model of CPVT. 106 
Summary
Proteins responsible for regulation of intracellular Ca 2ϩ handling have been implicated in genetic diseases. In particular, mutations in the RYR2 gene encoding the cardiac ryanodine receptor isoform 2 and the CASQ2 gene encoding the cardiac calsequestrin isoform 2 cause a clinical condition called CPVT that is highly lethal and often manifests in the pediatric population. RyR2 mutations result in an abnormal protein that is prone to spontaneous Ca 2ϩ release from the SR. Mutations in the cardiac calsequestrin reduce the amount of protein and Ca 2ϩ buffering in the SR. In vitro studies and development of knock-in mice have provided important information that have advanced the field and suggest that SOICR is likely to be the common mechanism for a variety of mutations in these 2 genes. The field has been particularly productive in bringing advancements to the clinics where new therapies have already been introduced. Advances in our understanding of the regulation of intracellular Ca 2ϩ in health and disease will facilitate the development of novel risk stratification and management scheme to improve survival and quality of life of CPVT patients.
